Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
144 results about "Degenerative Disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A disease in which the function or structure of the affected tissues or organs changes for the worse over time. Osteoarthritis, osteoporosis, and Alzheimer's disease are examples.
Antibody inhibitors of GDF-8 and uses thereof
ActiveUS7320789B2Reduction in one or more of the biological activitiesReduced activityNervous disorderMuscular disorderAntibody inhibitorAntibody fragments
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
Owner:WYETH LLC
Production of oligodendrocytes from placenta-derived stem cells
The present invention provides methods and compositions for the production of glial cells and oligodendrocytes from placenta stem cells. The invention further provides for the use of these glia and oligodendrocytes in the treatment of, and intervention in, for example, trauma, ischemia and degenerative disorders of the central nervous system (CNS), particularly in the treatment of demyelinating diseases such as multiple sclerosis.
Owner:CELULARITY INC
Implant system and method to treat degenerative disorders of the spine
InactiveUS20080058807A1Internal osteosythesisJoint implantsDegenerative DisorderSpinal Degenerative Disease
Owner:SPARTEK MEDICAL
Treatment of stroke and other acute neural degenerative disorders using postpartum-derived cells
Owner:DEPUY SYNTHES PROD INC
Estrogen receptor modulators
Owner:MERCK SHARP & DOHME CORP
Agmatine, and polyaminoguanidine-bound heterocyclic compounds for neurotrauma and neurodegenerative diseases
InactiveUS6114392ABiocideIsocyanic acid derivatives preparationPhenothiazine derivativeDegenerative Disorder
The invention relates to the use of agmatine, in the treatment of acute neurotrauma (such as stroke) and degenerative disorders of the central and peripheral nervous system (such as dementia). The invention further provides novel compounds of general formula I (which are quinuclidine derivatives), formula II (which are norbornane derivatives), formula III (which are adamantane derivatives), and formula IV (which are phenothiazine derivatives): wherein R1, R2 and R3 are each independently hydrogen, hydroxy, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, halogeno, amino, phenyl, or R4NR5; R4 and R5 are each independently hydrogen, or (CH2)n-[NH(CH2)x]y-NHR6, or (CH2)n-[NH(CH2)x]y-NH-NHR6, or (CH2)n-[NH(CH2)x]y-(NR7=)CNHR6, or (CH2)n-[NH(CH2)x]y-NH(NR7=)CNHR6 wherein n is from 0-5, y is from 0-5 and each x is independently from 1-5; R6, and R7 are each independently hydrogen, hydroxy, substituted or unsubstituted C1-4 alkyl, substituted or unsubstituted C1-4 alkoxy, or halogeno; and pharmaceutically acceptable salts and optically active isomers thereof.
Owner:GILAD GAD M +1
2-(3-Aminoaryl)amino-4-aryl-thiazoles for the treatment of diseases
InactiveUS7423055B2Inhibiting signal transductionAntibacterial agentsOrganic active ingredientsArylThiazole
The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and / or inhibit signal transduction mediated by certain native and / or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.
Owner:AB SCIENCE
Selective estrogen receptor modulators
InactiveUS7157604B2Urea derivatives preparationBiocideHormone Receptor ModulatorsPercent Diameter Stenosis
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK & CO INC
Production of oligodendrocytes from placenta-derived stem cells
Owner:CELULARITY INC
2-arylbenzothiophene derivatives or pharceutically acceptable salts thereof, preparation method thereof, and pharceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as active ingredient
InactiveUS20100261727A1Suppress generationHigh binding affinityBiocideNervous disorderThiophene derivativesBULK ACTIVE INGREDIENT
2-arylbenzothiophene derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient. Since the 2-arylbenzothiophene derivatives of Formula 1 have a relatively high binding affinity for β-amyloid, they can be used as diagnostic reagents for diagnosing Alzheimer's disease at an early stage by non-invasive techniques when they are labeled with radioisotopes:wherein R1-R4, V, W, X, Y and Z are as defined in the Detailed Descript of the specification. Further, when the pharmaceutical composition containing the 2-arylbenzothiophene derivative binds with a low-molecular weight β-amyloid peptide binding compound, generation of malignant high-molecular weight β-amyloid deposits is minimized. Accordingly, the pharmaceutical composition can be used as a therapeutic agent of degenerative brain disease such as Alzheimer's disease.
Owner:IND UNIV COOP FOUND SOGANG UNIV
Piperidinyl-thiazole carboxylic acid derivatives as angiogenesis inhibitors
This invention relates to compounds of formula (I) and (II) that are useful in treating vascular endothelial growth factor (VEGF)-mediated disorders, particularly endometriosis and acute macular degenerative disorder. The invention also relates to a topical system for the treatment of acute macular degenerative disorder comprising a VEGF inhibitor.
Owner:DSPI
Methods of increasing muscle mass or muscle strength using antibody inhibitors of GDF-8
InactiveUS7731961B1Reduction in one or more of the biological activitiesReduced activityNervous disorderPeptide/protein ingredientsMuscle strengthAntibody inhibitor
The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.
Owner:WYETH LLC
Pharmaceutical delivery system for vitamin C and vitamin E and use of a combination of vitamin C and E for preventing or treating conditions involving oxidative stress
A pharmaceutical delivery system comprising a slow-release formulation of vitamin C (ascorbic acid) and a plain-release formulation of vitamin E (tocopherol) has been found to raise and maintain the concentrations of these vitamins in the blood plasma to a ratio of approximately 2.2:1. The steady-state concentration and ratio of these antioxidants has been found to be critical in the prevention and treatment of oxidative stress related disorders such as arteriosclerosis and diabetes and neural degenerative disorders such as Alzheimer's Disease.
Owner:AS FERROSAN
Treatment of CNS tumors with metalloprotease inhibitors
InactiveUS6025333AAvoid environmentIncrease the areaOrganic active ingredientsNervous disorderAbnormal tissue growthNervous system
The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include central nervous system myelin associated proteins and metalloproteases associated with glioblastoma cells and other malignant tumors which can metastasize to the brain. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system. The present invention is also directed to inhibitors of the metalloproteases. Such inhibitors in combination with the CNS myelin associated inhibitory proteins can be used in the treatment of malignant tumors.
Owner:ZURICH UNIV OF
Nutraceuticals for the treatment, protection and restoration of connective tissues
InactiveUS20050020500A1Smooth connectionIncrease blood flowOrganic active ingredientsPeptide/protein ingredientsMultiple formsConnective tissue fiber
The invention relates to a method for isolating from connective tissue a variety of glycosminoglycan (GAG)-polypeptide complexes and polypeptides which are substantially free of contaminating DNA and other molecules such as viruses which may be associated with the DNA in the cell. The invention also relates to uses of GAG-peptide complexes and polypeptides substantially free of DNA either directly, or after further processing, for the treatment, protection and restoration of connective tissues in inflammatory and degenerative disorders such as rheumatoid arthritis and osteoarthritis in any of their multiple forms or other degenerative conditions in mammals.
Owner:INST OF NUTRACEUTICAL RES
Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
Owner:DEPUY SYNTHES PROD INC
3-3-di-substituted-oxindoles as inhibitors of translation initiation
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK & CO INC
Compounds for the treatment of pathologies associated with aging and degenerative disorders
ActiveUS20120004263A1Preserved motor functionShorten the progressBiocideCosmetic preparationsMedicineDegenerative Disorder
The present invention relates to methods of inhibiting one or more signs of aging and / or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and / or reducing the severity and / or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.
Owner:UNIVERSITY OF PITTSBURGH
Estrogen receptor modulators
Owner:MERCK SHARP & DOHME LLC
Investigating neurological function
InactiveUS20090318825A1Promote resultsLarge and reliable differenceElectroencephalographySensorsMedicineDegenerative Disorder
This invention relates to a method and apparatus for identifying degenerative disorders and particularly to the early and accurate diagnosis of Alzheimer's Disease.
Owner:DIAGNOSTIC POTENTIALS
Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same
InactiveUS20130096126A1Easy to learnEnhance memoryOrganic active ingredientsBiocideAdrenergicAdrenergic receptor agonists
A method for enhancing learning or memory of both in a mammal having impaired learning or emory of both from a neuro-degenerative disorder, which entails the step of administering at least one compound or a salt thereof which is a β1-adrenergic receptor agonist, partial agonist or receptor ligand in an amount effective to improve the learning or memory or both of said mammal.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
XIAP therapy
InactiveUS20060269520A1Sufficient amountBiocideOrganic active ingredientsMedicineDegenerative Disorder
Owner:CHILDRENS HOSPITAL OF EASTERN ONTARIO
Novel iridoid compound with anti-Alzheimer's disease function
The invention discloses a serial of iridoids compounds with the structural formula (I), the application of the compounds in preparing medicaments applied to the prevention or treatment of nervous system degenerative disorders such as senile dementia and the like, the medical compositions containing the compounds and a preparation method of the compounds. The structural formula is as shown above, wherein, various groups are defined in the instruction.
Owner:BEIJING JOEKAI BIOTECH
2-propylene-1-ones as hsp70 inducer
Owner:TORRENT PHARMA LTD
Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
ActiveUS8518390B2Convenient treatmentHigh expressionBiocideGenetic material ingredientsTelomeraseMammal
Owner:DEPUY SYNTHES PROD INC
Thiazole and oxazole kinase inhibitors
The present invention is concerned with substituted azole derivatives that selectively modulate, regulate, and / or inhibit signal transduction mediated by certain native and / or mutant proteine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. In particular, several of these compounds are potent and selective Flt-3 inhibitors or / and syk inhibitors.
Owner:AB SCIENCE
Application of gastrodin to preparing medicaments for preventing and treating Alzheimer's disease
InactiveCN103385884AReduce inflammationImprove toleranceOrganic active ingredientsNervous disorderDiseaseAmyloid
The invention discloses an application of gastrodin to preparing medicaments for preventing and treating Alzheimer's disease. Alzheimer's disease (AD) is a neurodegenerative disease, and pathological characteristics comprise neuro fibrillary tangles formed in cells, hyperplasia of reactive microglia and glial cell, and the like, wherein the extracellular deposition of amyloid A beta is the main pathogenetic reason of AD. An AD small mouse taking a gastrodin-containing fodder is substantially improved in spatial-memory learning ability, substantially reduced in A beta level in brain and serum, and substantially reduced in amyloid plaques and microglia in brain tissue, and thus it is indicated that gastrodin is capable of preventing A beta deposition and decreasing active components causing AD mouse brain gastrodin.
Owner:KUNMING MEDICAL UNIVERSITY
Amide derivative
A compound of the formula: wherein Ar is optionally substituted phenyl, etc.; n is 0, 1 or 2;R1 is hydogen atom, optionally substituted alkyl, etc.; R2 and R3 are independently optionally substituted alkyl, etc.;R4 and R5 are independently hydrogen atom or optionally substituted alkyl; R6 is hydrogen atom, hydroxy or alkyl;or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders and the like.
Owner:SUMITOMO DAINIPPON PHARMA CO LTD
Intranasal administration of agents with pro-inflammatory activity for the therapy of neurological disorders
ActiveUS20140290647A1Stimulate endogenous productionPromote productionOrganic active ingredientsBiocideSerotoninNervous system
The invention concerns a product consisting of distilled water or of an aqueous solution hypotonic or substantially isotonic with respect to blood plasma or, less preferably, hypertonic with respect to blood plasma, to be administered on the nasal mucosa according to a specific operation mode in order to cause an inflammation of an irritative kind, for use in a treatment of stimulation of the endogenous production of inflammatory mediators, in the therapy and prevention of neurological disorders, in particular of degenerative disorders of the central and peripheral nervous system. The inflammatory mediators the endogenous production of which is stimulated comprise NGF, neurotrophin-3, neurotrophin-4, serotonin, substance P, heparin, ECF-A.
Owner:SALVINELLI BEATRICE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com